Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Empagliflozin (JARDIANCE^®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

How confident are you to start Empagliflozin to non-T2D HF patients?

Document ID: PC-PH-105098

04/01/2024

Author: Boehringer Ingelheim

Related content